# Coherus Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coherus-biosciences

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.coherus.com/
- Total disclosed funding: $60M
- Latest round: Series C (May 19, 2014)
- Investors on record: 9

## About

Founded in 2010, Coherus Biosciences, Inc. is dedicated to developing cancer therapies. The company has engaged in 10 deals since its inception, raising a total of USD 50.00 mn, with its latest funding occurring in November 2014 through a Private Placement/Follow on that netted USD 50.00 mn. The headquarters is located in Redwood City, California, and the firm has made notable strides in its business strategy over the years, concentrating on immuno-oncology. The CEO and founder's history are not explicitly stated, but the company has shown a consistent focus on advancing its therapeutic offerings.

Coherus Oncology develops and commercializes immuno-oncology therapies that enhance treatment outcomes for patients with difficult cancer types. Their flagship product, LOQTORZI® (toripalimab-tpzi), is the only FDA-approved therapy for recurrent or metastatic nasopharyngeal carcinoma (NPC), offered as a standalone or in combination with chemotherapy. The pipeline includes several clinical-stage candidates designed to target the tumor microenvironment, with ongoing trials to evaluate their efficacy against various cancers. The company primarily serves healthcare providers and institutions across the United States and select international markets, emphasizing innovative solutions for patients.

In 2024, Coherus Oncology reported a revenue of USD 266.96 mn. The company’s revenue primarily comes from the commercialization of its proprietary therapies, particularly LOQTORZI®, sold directly to healthcare facilities and specialists in cancer treatment. The pricing for LOQTORZI® and investigational therapies is shaped by market dynamics and healthcare reimbursement systems, ensuring access for patients in need.

Coherus Biosciences plans to utilize the USD 50.00 mn raised in November 2014 to further its development initiatives, refine its partnering strategies, and deliver essential therapeutics. The company is focused on launching new products, enhancing its pipeline for new therapy candidates, and expanding into additional markets. Specific geographic regions targeted for expansion will be identified as opportunities arise, and the company anticipates leveraging funding to support these strategic initiatives.

## Funding rounds

- Series C, May 19, 2014, $55M — KKR, Sofinnova Investments, Lilly Ventures, Venrock, Vivo Capital, F-Prime Capital, Idera Capital Management Corporation Ltd., RA Capital Management, Rock Springs Capital
- Series B, Feb 21, 2014, $5.2M — Sofinnova Investments

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B, Series C
- KKR (https://capitalatlas.ai/funds/kkr) — Series C
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C
- Idera Capital Management Corporation Ltd. — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C